External validation of biochemical recurrence definition to predict oncologic outcomes following focal therapy for localized prostate cancer using high intensity focused ultrasound

Abstract

AbstractPurposeThis is an external validation of several biochemical recurrence definitions based on prostate specific antigen criteria (PSA). The purpose is to predict the need of additional treatment and failure after focal therapy using high intensity focused ultrasound (HIFU) for localized prostate cancer (PCa).Materials and MethodsA total of 343 consecutive patients who underwent HIFU with Ablatherm® and Focal One® devices between June 2001 and November 2020 were identified. Treatment failure was defined as clinically significant PCa on postoperative biopsy, the need for salvage radical or systematic treatment, metastasis, or PCa‐related death. The biochemical recurrence definitions tested were PSA nadir, time to PSA nadir, percentage of PSA reduction, Huber et al. criteria defined as PSA nadir + 1 ng/mL at 12 months or PSA nadir + 1.5 ng/mL at 24−36 months. Multivariable Cox regression analysis and decision‐curve analysis were used to validate and compare criteria. Kaplan−Meier analysis was used to assess criteria associated with the highest accuracy.ResultsOne hundred seventy‐eight patients met the inclusion criteria and were analyzed. Overall, 61 (34%) and 41 (23%) patients had an additional treatment and failure with a median follow‐up of 52 months. At multivariable analysis, model including Huber et al. criteria exhibited the highest Harrell's C‐index for the prediction of the need of additional treatment (hazard ratio [HR]: 10, p < 0.001, c‐index: 84%) and treatment failure (HR: 9.1, p < 0.001, c‐index: 82%) as well as higher net benefit. The 60‐months need of additional treatment and treatment failure‐free survival were 89% and 98% compared to 26% and 49%, respectively, when stratified according to Huber et al. criteria (Log‐rank test, p < 0.001). Similar results were found after excluding patient with non‐clinically significant PCa at initial biopsy.ConclusionsWe report an external validation of biochemical recurrence definitions predicting the need of additional treatment and failure after focal therapy using HIFU for localized PCa. Huber et al. criteria were identified as the most accurate and could be used to guide clinicians toward further evaluation and salvage treatments.